136 related articles for article (PubMed ID: 32988862)
21. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
22. The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
Ekizoglu S; Dogan S; Ulker D; Seven D; Gozen ED; Karaman E; Buyru N
Clin Otolaryngol; 2015 Dec; 40(6):622-8. PubMed ID: 25850957
[TBL] [Abstract][Full Text] [Related]
23. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
24. p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma.
Wu D; Cheng J; Sun G; Wu S; Li M; Gao Z; Zhai S; Li P; Su D; Wang X
Oncotarget; 2016 Jun; 7(24):36539-36550. PubMed ID: 27174914
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
26. The effect of miR-579 on the PI3K/AKT pathway in human glioblastoma PTEN mutant cell lines.
Kalhori MR; Irani S; Soleimani M; Arefian E; Kouhkan F
J Cell Biochem; 2019 Oct; 120(10):16760-16774. PubMed ID: 31243804
[TBL] [Abstract][Full Text] [Related]
27. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
28. Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer.
Laudański P; Kowalczuk O; Klasa-Mazurkiewicz D; Milczek T; Rysak-Luberowicz D; Garbowicz M; Baranowski W; Charkiewicz R; Szamatowicz J; Chyczewski L
Folia Histochem Cytobiol; 2011; 49(2):317-24. PubMed ID: 21744334
[TBL] [Abstract][Full Text] [Related]
29. Rheb, an activator of target of rapamycin, in the blackback land crab, Gecarcinus lateralis: cloning and effects of molting and unweighting on expression in skeletal muscle.
MacLea KS; Abuhagr AM; Pitts NL; Covi JA; Bader BD; Chang ES; Mykles DL
J Exp Biol; 2012 Feb; 215(Pt 4):590-604. PubMed ID: 22279066
[TBL] [Abstract][Full Text] [Related]
30. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
[TBL] [Abstract][Full Text] [Related]
31. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
[TBL] [Abstract][Full Text] [Related]
32. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
[TBL] [Abstract][Full Text] [Related]
33. Mechanistic target of rapamycin (mTOR) signaling genes in decapod crustaceans: cloning and tissue expression of mTOR, Akt, Rheb, and p70 S6 kinase in the green crab, Carcinus maenas, and blackback land crab, Gecarcinus lateralis.
Abuhagr AM; Maclea KS; Chang ES; Mykles DL
Comp Biochem Physiol A Mol Integr Physiol; 2014 Feb; 168():25-39. PubMed ID: 24269559
[TBL] [Abstract][Full Text] [Related]
34. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
35. Expression and alterations of the PTEN / AKT / mTOR pathway in ameloblastomas.
Scheper MA; Chaisuparat R; Nikitakis NG; Sauk JJ
Oral Dis; 2008 Sep; 14(6):561-8. PubMed ID: 18826385
[TBL] [Abstract][Full Text] [Related]
36. miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway.
Wang P; Guan Q; Zhou D; Yu Z; Song Y; Qiu W
DNA Cell Biol; 2018 Jan; 37(1):38-45. PubMed ID: 29185784
[TBL] [Abstract][Full Text] [Related]
37. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
[TBL] [Abstract][Full Text] [Related]
38. Control of a tumor suppressor PDCD4: Degradation mechanisms of the protein in hepatocellular carcinoma cells.
Matsuhashi S; Hamajima H; Xia J; Zhang H; Mizuta T; Anzai K; Ozaki I
Cell Signal; 2014 Mar; 26(3):603-10. PubMed ID: 24334270
[TBL] [Abstract][Full Text] [Related]
39. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
[TBL] [Abstract][Full Text] [Related]
40. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients.
Clark C; Shah S; Herman-Ferdinandez L; Ekshyyan O; Abreo F; Rong X; McLarty J; Lurie A; Milligan EJ; Nathan CO
Laryngoscope; 2010 Jun; 120(6):1159-65. PubMed ID: 20513033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
